Nutley, NJ, United States of America

Emily Aijun Liu



Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 224(Granted Patents)


Location History:

  • Basking Ridge, NJ (US) (2006)
  • Nutley, NJ (US) (2001 - 2008)
  • Burlingame, CA (US) (2011)

Company Filing History:


Years Active: 2001-2011

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Emily Aijun Liu: Innovator in Pharmaceutical Compounds

Introduction

Emily Aijun Liu is a prominent inventor based in Nutley, NJ (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that show promise in cancer treatment. With a total of 10 patents to her name, Liu's work is characterized by innovation and a commitment to improving health outcomes.

Latest Patents

Liu's latest patents focus on CIS-imidazolines, which are compounds that exhibit antiproliferative activity. The first patent describes a process for manufacturing these compounds and their pharmaceutically acceptable salts and esters. These compounds are recognized for their potential use as active agents in medicaments aimed at treating cancer. The second patent further elaborates on compounds that inhibit the interaction of MDM2 protein with a p53-like peptide, reinforcing their role in cancer therapy.

Career Highlights

Throughout her career, Emily Aijun Liu has worked with notable companies, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. Her experience in these organizations has allowed her to develop and refine her innovative ideas in pharmaceutical research.

Collaborations

Liu has collaborated with esteemed colleagues such as Norman Kong and Binh Vu. These partnerships have contributed to her success and the advancement of her research in the pharmaceutical field.

Conclusion

Emily Aijun Liu stands out as a dedicated inventor whose work in pharmaceutical compounds has the potential to make a significant impact on cancer treatment. Her innovative spirit and collaborative efforts continue to drive advancements in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…